Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Europe

Trouble In Iceland: DeCODE Scrambles To Escape Cash Crisis

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Personalized medicine firm digs its way out of suffocating debt, hoping mystery investors will help the company survive 2009.

You may also be interested in...



DeCode Enters Bankruptcy, Looks To Sell Assets To Its Former VCs

Saddled by $314 million in debt, the Icelandic firm files for Chapter 11 protection.

DeCode Enters Bankruptcy, Looks To Sell Assets To Its Former VCs

Saddled by $314 million in debt, the Icelandic firm files for Chapter 11 protection.

Companion Dx Pioneers Test Variety Of Business Models

Regulatory environment opens up, but alliances with Pharma have yet to take off.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical Europe
Latest Headlines

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

See All
UsernamePublicRestriction

Register

PS069303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By